Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

RENEW 4

Novo Nordisk · Phase 3 · Recruiting · Enrollment 285

NCT07745504

ArmPopulationDoseWeeksEstimandWeight change
Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2Obesity or overweightn/r26n/rn/r
Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1Obesity or overweightn/r26n/rn/r
Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1Obesity or overweightn/r26n/rn/r